

David Caballero appointed Managing Director of HIPRA Animal Health to drive the company's global growth

The executive, who has built a strong international career within the company, will lead the strategic development of the animal health division at a key moment in HIPRA's evolution and expansion

Girona, May 28, 2026 – HIPRA has appointed **David Caballero as the company's new Managing Director of Animal Health**, a position he will officially assume on June 1st. With this appointment, the company reinforces its commitment to internal talent and to consolidating a new phase of growth and international expansion for its animal health division.

David Caballero has developed his entire professional career within the animal health industry, most recently leading HIPRA's Global Animal Business Division. His profile combines **extensive experience in business development, international leadership, and strategic knowledge of the veterinary sector**, having recently played a key role in the company's global evolution and in strengthening its position in strategic markets.

A graduate in Veterinary Medicine with specialized training in business management and administration, Caballero has **more than two decades of experience** linked to the field of animal health. Throughout these years, he has led multidisciplinary teams and international projects aimed at driving company growth, innovation, and closer relationships with clients and professionals across the sector.

This leadership transition forms part of HIPRA's strategy to continue **strengthening its animal health division** by enhancing its innovation capabilities and consolidating its international presence in an environment shaped by new health, production, and regulatory challenges.

"It is an honor to take on this new professional challenge within a company with such a clear vision for the future and a strong commitment to innovation and animal health. I approach this new stage with the determination to **continue driving HIPRA's global growth** and generating value for our clients, partners, and the sector as a whole," said David Caballero.

With this appointment, HIPRA reaffirms its commitment to a growth model based on specialization, scientific innovation, and the development of internal talent as key drivers for continuing to advance differentiated solutions for prevention and animal health.



About HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention in animal and human health (One Health), with a wide range of highly innovative vaccines and an advanced diagnostic service. With its claim “**Building immunity for a healthier world**”, HIPRA reaffirms its commitment to contributing solutions that improve global health.

The company has a strong international presence with **40 subsidiaries, 3 R&D centers and 6 production facilities** strategically located in Europe (Spain) and the Americas (Brazil). In addition, its extensive international distribution network keeps commercial channels open in nearly 100 additional countries, thus covering all five continents.

Research and development are at the core of its expertise. HIPRA **invests around the 15% of its annual revenue to R&D** activities, focused on the creation and application of the latest scientific advances for the development of innovative vaccines of the highest quality. HIPRA has a portfolio of vaccines based on different technological platforms, with R&D teams working with a broad range of technologies and biological modalities.

To add further value to its expertise in vaccination, the company also develops medical devices and traceability services for animal health.

Press contacts

Irene Calle – icalle@harmon.es – M. 609 873 052

José María Nieto – jnieto@harmon.es – M. 689 186 062